<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20210425200643+02'00'</creation_date><modification_date>D:20210425200805+02'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-04-273_h_epar-other_2.pdf</pdf_file></head><body><section><header>official address  domenico scarlattilaan 6  ●  1083 hs amsterdam  ●  the netherlands an agency of the european union     address for visits and deliveries  refer to www.ema.europa.eu/how-to-find-us  send us a question  go to www.ema.europa.eu/contact  telephone +31 (0)88 781 6000   © european medicines agency, 2021. reproduction is authorised provided the source is acknowledged. 
 28 january 2021   ema/30770/2021  
 committee for medicinal products for human use (chmp) 
 scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s) 
  active substance(s): mitotane procedure no. emea/h/c/psusa/00002075/202004 
 period covered by the psur: 27 april 2017 to 27 april 2020 
       scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)  
 ema/30770/2021
  
 page 2/2</header></section><section><header>scientific conclusions</header><p>taking into account the prac assessment report on the psur(s) for mitotane, the scientific conclusions of chmp are as follows:</p><p>
 in view of available data on risk(s) from clinical trial(s), the literature, spontaneous reports and in view 
 of a plausible mechanism of action, the prac considers a causal relationship between mitotane and 
 hypogonadism is at least a reasonable possibility. the prac concluded that the product information of 
 products containing mitotane should be amended accordingly. 
 the chmp agrees with the scientific conclusions made by the prac.</p></section><section><header>grounds for the variation to the terms of the marketing authorisation(s)</header><p>on the basis of the scientific conclusions for mitotane the chmp is of the opinion that the benefit-risk balance of the medicinal product(s) containing mitotane is unchanged subject to the proposed changes 
 to the product information 
 the chmp recommends that the terms of the marketing authorisation(s) should be varied.</p></section></body></xml>